|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Endoscopic retrograde cholangiopancreatography in cirrhosis-a systematic review and meta-analysis focused on adverse events显示文摘AIM To investigate indications and outcomes of endoscopic retrograde cholangiopancreatography(ERCP) in cirrhotics, especially adverse events. Patients with cirrhosis undergoing ERCP are believed to have increased risk. However, there is a paucity of literature describing the indications and outcomes of ERCP procedures in patients with cirrhosis, especially focusing on adverse events.METHODS We performed a systematic appraisal of major literature databases, including PubMed and EMBASE, with a manual search of literature from their inception until April 2017.RESULTS A total of 6,505 patients from 15 studies were analyzed(male ratio 59%, mean age 59 years), 11% with alcoholic and 89% with non-alcoholic cirrhosis, with 56.2% Child-Pugh class A, and 43.8% class B or C. Indications for ERCP included choledocholithiasis 60.9%, biliary strictures 26.2%, gallstone pancreatitis 21.1% and cholangitis 15.5%. Types of interventions included endoscopic sphincterotomy 52.7%, biliary stenting 16.7% and biliary dilation 4.6%. Individual adverse events included hemorrhage in 4.58%(95%CI: 2.77-6.75%, I^2 = 85.9%), post-ERCP pancreatitis(PEP) in 3.68%(95%CI: 1.83-6.00%, I^2 = 89.5%), cholangitis in 1.93%(95%CI: 0.63-3.71%, I^2 = 87.1%) and perforation in 0.00%(95%CI: 0.00-0.23%, I^2 = 37.8%). Six studies were used for comparison of ERCPrelated complications in cirrhosis vs non-cirrhosis, which showed higher overall rates of complications in cirrhosis patients with pooled OR of 1.63(95%CI: 1.27-2.09, I2 = 65%): higher rates of hemorrhage with OR of 2.05(95%CI: 1.62-2.58, I^2 = 2.1%) and PEP with OR of 1.33(95%CI: 1.04-1.70, I2=65%), but similar cholangitis rates with OR of 1.23(95%CI: 0.67-2.26, I^2 = 44.3%).CONCLUSION There is an overall higher rate of adverse events related to ERCP in patients with cirrhosis, especially hemorrhage and PEP. A thorough risk/benefit assessment should be performed prior to undertaking ERCP in patients with cirrhosis. | Shailender Singh Mashiana Amaninder Singh Dhaliwal Harlan Sayles Banreet Dhindsa Ji Won Yoo Qing Wu shailender singh Ali A Siddiqui Gordon Ohning Mohit Girotra Douglas G Adler | 2018 | World Journal of Gastrointestinal Endoscopy2018，10，11： | 6 |
| 2 | End-stage renal disease is associated with increased post endoscopic retrograde cholangiopancreatography adverse events in hospitalized patients显示文摘AIM To determine if end-stage renal disease (ESRD) is a risk factor for post endoscopic retrograde cholangio-pancreatography (ERCP) adverse events (AEs). METHODS We performed a retrospective cohort study using the Nationwide Inpatient Sample (NIS) 2011-2013. We identified adult patients who underwent ERCP using the International Classification of Diseases 9^(th) Revision (ICD-9-CM). Included patients were divided into three groups: ESRD, chronic kidney disease (CKD), and control. The primary outcome was post-ERCP AEs including pancreatitis, bleeding, and perforation determined based on specific ICD-9-CM codes. Secondary outcomes were length of hospital stay, in-hospital mortality, and admission cost. AEs and mortality were compared using multivariate logistic regression analysis.RESULTS There were 492175 discharges that underwent ERCP during the 3 years. The ESRD and CKD groups contained 7347 and 39403 hospitalizations respectively, whereas the control group had 445424 hospitalizations. Post-ERCP pancreatitis (PEP) was significantly higher in the ESRD group (8.3%) compared to the control group (4.6%) with adjusted odd ratio (aOR) = 1.7 (95% CI: 1.4-2.1, ~aP < 0.001). ESRD was associated with significantly higher ERCP-related bleeding (5.1%) compared to the control group 1.5% (aOR = 1.86, 95%CI: 1.4-2.4, ~aP < 0.001). ESRD had increased hospital mortality 7.1% vs 1.15% in the control OR = 6.6 (95%CI: 5.3-8.2, ~aP < 0.001), longer hospital stay with adjusted mean difference (aMD) = 5.9 d (95% CI: 5.0-6.7 d, ~aP < 0.001) and higher hospitalization charges aMD = $+82064 (95%CI: $68221-$95906, ~aP < 0.001). CONCLUSION ESRD is a risk factor for post-ERCP AEs and is associated with higher hospital mortality. Careful selection and close monitoring is warranted to improve outcomes. | Tarek Sawas Fateh Bazerbachi Samir Haffar Won K Cho Michael J Levy John A Martin Bret T Petersen Mark D Topazian Vinay Chandrasekhara Barham K Abu Dayyeh | 2018 | World Journal of Gastroenterology2018，24，41： | 2 |
| 3 | Cancer-associated fibroblast-derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib显示文摘Background:Cancer-associated fibroblasts(CAFs)play an important role in the induction of chemo-resistance.This study aimed to clarify the mechanism underlying CAF-mediated resistance to two tyrosine kinase inhibitors(TKIs),sorafenib and lenvatinib,and to identify a novel therapeutic target for overcoming TKI resistance in hepatocellular carcinoma(HCC).Methods:We performed a systematic integrative analysis of publicly available gene expression datasets and whole-transcriptome sequencing data from 9 pairs of CAFs and para-cancer fibroblasts isolated from human HCC and para-tumor tissues,respectively,to identify key molecules that might induce resistance to TKIs.We then performed in vitro and in vivo experiments to validate selected targets and related mechanisms.The associations of plasma secreted phosphoprotein 1(SPP1)expression levels before sorafenib/lenvatinib treatment with progression-free survival(PFS)and overall survival(OS)of 54 patients with advanced HCC were evaluated using Kaplan-Meier and Cox regression analysis.Results:Bioinformatic analysis identified CAF-derived SPP1 as a candidate molecule driving TKI resistance.SPP1 inhibitors reversed CAF-induced TKI resistance in vitro and in vivo.CAF-derived SPP1 activated rapidly accelerated fibrosarcoma(RAF)/mitogen-activated protein kinase(MAPK)and phosphatidylinositol 3-kinase(PI3K)/protein kinase B(AKT)/mammalian target of rapamycin(mTOR)through the integrin-protein kinase C-alpha(PKCα)signaling pathway and promoted epithelial-to-mesenchymal transition(EMT).A high plasma SPP1 level before TKI treatment was identified as an independent predictor of poor PFS(P=0.026)and OS(P=0.047)in patients with advanced HCC after TKI treatment.Conclusions:CAF-derived SPP1 enhances TKI resistance in HCC via bypass activation of oncogenic signals and EMT promotion.Its inhibition represents a promising therapeutic strategy against TKI resistance inHCC.Moreover,plasma SPP1 level before TKI treatment represents a potential biomarker for treatment response prediction. | JungWoo Eun Jung Hwan Yoon Hye Ri Ahn Seokhwi Kim Young Bae Kim Su Bin Lim Won Park TaeWook Kang Geum Ok Baek Moon Gyeong Yoon Ju A Son Ji HyangWeon Soon Sun Kim Hyo Jung Cho Jae Youn Cheong | 2023 | Cancer Communications2023，43，4： | 2 |
| 4 | Catalysts for electrochemical ammonia oxidation:Trend,challenge,and promise显示文摘Developing sustainable and clean energy technology is critial to address the current energy and environmental crisis.As an energy carrier,hydrogen has been getting attention due to its abundance,high energy density,and zero carbon emission.Due to the difficulty of hydrogen storage and transport,the electro-oxidation of ammonia shows great potential for renewable energy since it satisfies both energy supply and environmental protection as a carbon-free fuel with high hydrogen content.However,ammonia electro-oxidation is a sluggish reaction and shows low durability.Understanding the complicated mechanism and intermediates is conducive to developing efficient electrocatalysts with high catalytic activity and durability.This review begins with the ammonia oxidation technologies and their principles.The two typical mechanisms for ammonia electro-oxidation,Oswin-Salomon mechanism and Gerischer-Mauerer mechanism,are discussed,and attention to the poisoning species is included.Then,the electrocatalysts for ammonia reaction are classified into Pt-based catalysts and non-noble metal-based catalysts,and their performances are reviewed with various strategies.Based on the progress on the electrochemical ammonia oxidation catalysts,the challenges and future insight on ammonia oxidation reaction are discussed and proposed. | Sol A Lee Mi Gyoung Lee Ho Won Jang | 2022 | Science China Materials2022，65，12： | 2 |
| 5 | 胆固醇酯转移蛋白基因的蛋白质截断型变异体与冠状动脉性心脏病风险的关系显示文摘随机对照试验结果表明,抑制胆固醇酯转运蛋白(cholesteryl ester transfer protein,CETP)的疗法并不能降低冠状动脉性心脏病(coronary heart disease,CHD)的发生风险。研究失败的可能原因包括靶目标无效、靶目标外小分子的不良反应和随机对照设计因素影响等。在编码药物靶点的基因中具有天然存在的遗传变异,以此为基础,人类研究可以深入了解针对基因产物的治疗的潜在功效和安全性。 | Nomura A Won HH Khera AV Takeuchi F Ito K McCarthy S Emdin CA Klarin D Natarajan P Zekavat SM Gupta N Peloso GM Borecki IB Teslovich TM Asselta R Duga S Merlini PA Correa A Kessler T Wilson JG Bown MJ Hall AS Braund PS Carey DJ Murray MF Kirchner HL Leader JB Lavage DR Manus JN Hartze DN Samani NJ Schunkert H Marrugat J Elosua R McPherson R Farrall M Watkins H Juang JJ Hsiung CA Lin SY Wang JS Tada H Kawashiri MA Inazu A Yamagishi M Katsuya T Nakashima E Nakatochi M Yamamoto K Yokota M Momozawa Y Rotter JI Lander ES Rader DJ Danesh J Ardissino D Gabriel S Willer CJ Abecasis GR Saleheen D Kubo M Kato N Ida Chen YD Dewey FE Kathiresan S 刘莉 叶鹏 | 2017 | 中华高血压杂志2017，25，9： | 2 |
| 6 | GEM-2:A new multifrequency electro- magnetic sensor显示文摘 | Won I J Keiswetter D A Fields G RA and Sutton L C | 1996 | Journal of Environmental and Engineering Geophysics1996，1，2： | 1 |
| 7 | New CT response criteria in non-small cell lung cancer: Proposal and application in EGFR tyrosine kinase inhibitor therapy显示文摘 | Ho Yun Lee Kyung Soo Lee Myung-Ju Ahn Hye Sun Hwang Ju Won Lee Keunchil Park Jin Seok Ahn Tae Sung Kim Chin A Yi Myung Jin Chung | 2010 | Lung Cancer2010，，： | 1 |
| 8 | Purification of recombinant human epidermal growth factor secreted from the methylotrophic yeast Hansenula polymorpha 显示文摘 | Heo J H Won H S Kang H A | 2002 | Protein Expr Purif2002，24，： | 1 |
| 9 | 查看详情显示文摘 | Kim A Won Y Woo K Hu P Wang Z Zhang M Shi L | | 0，，02： | 1 |
| 10 | Toxaphene affects the lev- els of mRNA transcripts that encode antioxidant enzymes in Hydra显示文摘 | Woo S Lee A Won H | 2012 | Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacologyl2012，156，： | 1 |
| 11 | Numerical Heat Transfer Studies of the Fatty Acids for Different Heat Ex- changer Materials on the Performance of a Latent Heat Storage System 显示文摘 | Sharma A Won L D Buddhi D | 2005 | Renew Energy2005，30，14： | 1 |
| 12 | Ultra-wideband radio 显示文摘 | Scholtz R A Pozar D and Won N | 2005 | EURASIP Journal on Applied Signal Processing2005，3，1： | 1 |
| 13 | Flameless oxi-dation to reduce thermal NO formation 显示文摘 | WUNNING J A WONNING J G | 1997 | Pro- gress in Energy and Combustion Science1997，23，： | 1 |
| 14 | Efficient soft input soft-output tree detection via an improved path metric 显示文摘 | Choi Jun Won Shim Byonghyo Singer A C | 2012 | IEEE Transactions on Information Theory2012，58，3： | 1 |
| 15 | Adult tethered cord syndrome: relative to spinal cord length and filum thickness显示文摘 | Yamada S Won D J Yamada SM Hadden A Siddiqi J | 2004 | Neurol Res2004，26，7： | 1 |
| 16 | Kinetics and mechanism of the deearboxylation of anthranilic acid in aqueous solution 显示文摘 | Willi A V Won C M Vilk P | 1968 | The Journal of Physical Chemistry1968，72，9： | 1 |
| 17 | Microstructural evo- lution and mechanical properties of low alloy ste~l tem- pered by induction heating 显示文摘 | SOON T A DAE S K WON J N | 2005 | Materials processing Technology2005，160，： | 1 |
| 18 | Economic growth and interfactor/interfuel sub-stitution in Korea显示文摘 | WON J A | 2004 | Energy Economics2004，26，1： | 1 |
| 19 | A comprehensive 1000 Ge- nomes-based genome-wide association meta-analysis of coronary ar- tery disease 显示文摘 | Nikpay M Goel A Won HH | 2015 | Nat Genet2015，47，10： | 1 |
| 20 | Long term resuits of total hip arthroplasty with acemented custom designed swan neck femora component for congenital dislocation or severe dysplasia 显示文摘 | Fazio Frank Di Won Yong Shon Salvati Eduardo A | 2002 | J Boneand Joint Surg (Am)2002，84，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员